glp-1 resistant food research Frontiers Consumers' Expectations about GLP-1 Drugs

Cyklizacja poprzez wizanie laktonowe midzy Asp i Lys oraz obecno D-fenyloalaniny zwikszaj odporno na degradacj enzymatyczn

First cardiovascular safety trial to demonstrate that a GLP-1R agonist reduces MACE and microvascular (including renal) events in patients with T2DM and high cardiovascular risk

Moving from insulin to GLP-1 A patient on basal insulin whose Type 2 diabetes is relatively well controlled might transition to a GLP-1 agonist if they are gaining excessive weight on insulin, want to simplify their regimen, have developed cardiovascular risk factors that would benefit from GLP-1 protection, or have adequate remaining beta cell function

It overlaps with both but isnt identical to either